EPAS1 and nonpapillary renal cell carcinoma: PT2385 inhibited the expression of HIF2α-dependent genes, including VEGF-A, PAI-1, and cyclin D1 in ccRCC cell lines and tumor xenografts [80]; and treatment of tumor-bearing mice with PT2385 caused tumor regressions, suggesting HIF2α is a pivotal oncogenic driver of human ccRCC [80].